이노비오 파마슈티컬스(INO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.24 (+2.48%), 시가총액 $0.12B, 52주 최저~최고 $1.05 ~ $2.87.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesio
이노비오 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이노비오 파마슈티컬스의 현재 주가는 $1.24 (+2.48%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이노비오 파마슈티컬스의 시가총액은 약 $0.12B입니다.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human pap